These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3403257)

  • 41. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers.
    Eriksson E; Modigh K; Carlsson A; Wikström H
    Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate].
    Baranowska B; Jeske W; Szymanowski J; Piechna K
    J Urol (Paris); 1983; 89(8):601-5. PubMed ID: 6203986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letter: Prolactin, levodopa, and migraine.
    Parantainen J
    Lancet; 1975 Feb; 1(7904):467. PubMed ID: 48666
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man.
    Sowers JR; Sharp B; McCallum RW
    J Clin Endocrinol Metab; 1982 Apr; 54(4):869-71. PubMed ID: 7037817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibitory effect of calcium on serum prolactin.
    Kruse K; Kracht U
    Acta Endocrinol (Copenh); 1981 Nov; 98(3):339-44. PubMed ID: 7293666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine and migraine.
    Barbanti P; Fabbrini G; Cerbo R
    Neurology; 1998 Sep; 51(3):925. PubMed ID: 9748079
    [No Abstract]   [Full Text] [Related]  

  • 47. [The dopamine receptor. Target of various diseases].
    Herschel M
    Fortschr Med; 1987 Feb; 105(5):86-8. PubMed ID: 2881870
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of 3-PPP, a putative dopamine autoreceptor agonist, on rat serum prolactin levels.
    Meltzer HY; Simonovic M
    Life Sci; 1981 Jul; 29(1):99-105. PubMed ID: 7196483
    [No Abstract]   [Full Text] [Related]  

  • 49. The dopamine of the rat mammotroph in cell culture as a model for drug action.
    Mowles TF; Burghardt B; Burghardt C; Charnecki A; Sheppard H
    Life Sci; 1978 Jun; 22(23):2103-12. PubMed ID: 672449
    [No Abstract]   [Full Text] [Related]  

  • 50. Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion.
    Carlsson M; Eriksson E; Nilsson C; Carlsson A
    Neuropharmacology; 1986 Aug; 25(8):951-4. PubMed ID: 3774120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.
    Ferrari C; Rampini P; Paracchi A; Boghen M; Mailland F
    Eur J Clin Pharmacol; 1985; 27(6):707-11. PubMed ID: 3921384
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The dopamine autoreceptor agonist, (+/-)-trans-1,3,4,4a5,10b-hexahydro-4-propyl-2H [1]benzopyrano [3,4-b] pyridin-9-ol hydrochloride (CGS 15855A), modulates striatal dopamine metabolism and prolactin release.
    Iyengar S; Hausler A; Kim HS; Marien M; Altar CA; Wood PL
    Neuropharmacology; 1989 Jan; 28(1):27-31. PubMed ID: 2522597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of dopaminergic blockade on the secretion of growth hormone and prolactin in man.
    Masala A; Delitala G; Alagna S; Devilla L; Rovasio PP; Lotti G
    Metabolism; 1978 Aug; 27(8):921-6. PubMed ID: 672613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine and migraine: biology and clinical implications.
    Akerman S; Goadsby PJ
    Cephalalgia; 2007 Nov; 27(11):1308-14. PubMed ID: 17970991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators.
    O'Connor JC; Cook JC; Craven SC; Van Pelt CS; Obourn JD
    Fundam Appl Toxicol; 1996 Oct; 33(2):182-95. PubMed ID: 8921337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats.
    Ekman A; Quiding M; Eriksson E
    Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevation of plasma prolactin concentrations by intravenous SCH 23390 and SKF 38393 in conscious rats.
    Tanimoto K; Tamminga CA; Chase TN
    Eur J Pharmacol; 1987 Dec; 144(2):147-51. PubMed ID: 3325296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pergolide, a potent long-acting dopamine-receptor agonist.
    Lemberger L; Crabtree R; Callaghan JT
    Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of dopamine blockade on gonadotropins and testosterone in men.
    Siris SG; Siris ES; van Kammen DP; Docherty JP; Alexander PE; Bunney WE
    Am J Psychiatry; 1980 Feb; 137(2):211-4. PubMed ID: 7352577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.